Tropisetron의 항암화학요법 후에 발생하는 급성 및 연성 오심의 조절 효과는 ondansetron과 비교하여 유의한 차이가 없었고 구토의 조절 효과에서도 두 군 사이에 유 의한 차이가 없었다. 부작용의 발생 빈도와 정도에서도 두 군 사이에 유의한 차이를 보이지 않았다. 그러나 하루 에 두 번 이상 투여해야 하는 ondansetron과는 달리 tropi setron은 하루에 한 번 투여하여 ondansetron과 비슷한 효 과를 얻을 수 있어서 투여 방법의 간편함을 고려할 때 tropisetron이 ondansetron과 함께 항암화학요법을 시행받 는 환자의 오심과 구토의 조절에 유용하게 사용될 수 있 을 것으로 사료된다.

Background & Aim: Nausea and vomiting are, from the patient`s viewpoint, by far the most distressing adverse effects related to the treatment with anticancer chemotherapy, especially with cisplatin-based chemotherapy. The purpose of this study was to evaluate the antiemetic effectiveness and tolerability of tropisetron (Navoban ) and ondansetron (Zofran ) in gynecologic cancer patients receiving cisplatin-based combination chemotherapy. Materials & Methods: Sixty seven patients receiving cisplatin-based combination chemotherapy were enrolled after randomization into two groups (group A and group B) and received either the tropisetron or the ondansetron respectively. The efficacy of controlling acute/delayed emesis and adverse effects were compared. Statistical analysis was performed using the Mantel-Haenszel test. Results: The efficacy of controlling nausea with tropisetron and ondansetron was 80.6% and 80.0% in day 1; 64.5% and 70.0% in day 2; 61.3% and 76.7% in day 3; 74.2% and 66.7% in day 4; 67.7% and 76.7% in day 5; 80.6% and 80.0% in day 6 respectively. The efficacy of controlling vomiting with tropisetron and ondansetron was 83.9% and 93.3% in day 1; 71.0% and 80.0% in day 2; 74.2% and 76.7% in day 3; 77.4% and 73.3% in day 4; 87.1% and 70.0% in day 5; 90.3% and 80.0% in day 6 respectively. Statistically all of these results were not significantly different. Headache, constipation and diarrhea were common adverse effects in both groups and these were not statistically significantly different in incidence and severity. Conclusions: Although the efficacy of tropisetron in controlling nausea/vomiting induced by cisplatin-based chemotherapy is not more excellent than that of ondansetron, it seems to be a clinically useful drug due to its simplicity of administration.